Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.43 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.43 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.43 |
| ▸ | GAPDH | P04406 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | STAT6 | P42226 | 1/20 | 0.43 |
| ▸ | PI4KA | P42356 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.43 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3067 | 1.00 | EGFR (0.46) | EGFRERBB2SLC29A1ADORA3SMN1; SMN2 | |
| SCHEMBL9447631 | 1.00 | EGFR (0.46) | EGFRERBB2SLC29A1ADORA3SMN1; SMN2 | |
| SCHEMBL30998177 | 1.00 | EGFR (0.46) | EGFRERBB2SLC29A1ADORA3SMN1; SMN2 | |
| SCHEMBL342030 | 1.00 | EGFR (0.46) | EGFRERBB2SLC29A1ADORA3SMN1; SMN2 | |
| SCHEMBL7898159 | 0.99 | EGFR (0.45) | EGFRERBB2SLC29A1ADORA3SMN1; SMN2 | |
| Water SCHEMBL8705007 | 0.99 | EGFR (0.45) | EGFRERBB2SLC29A1ADORA3SMN1; SMN2 | |
| Water SCHEMBL27310451 | 0.99 | EGFR (0.45) | EGFRERBB2SLC29A1ADORA3SMN1; SMN2 | |
| SCHEMBL7898163 | 0.99 | EGFR (0.45) | EGFRERBB2SLC29A1ADORA3SMN1; SMN2 | |
| Water SCHEMBL8705010 | 0.99 | EGFR (0.45) | EGFRERBB2SLC29A1ADORA3SMN1; SMN2 | |
| Water SCHEMBL7907737 | 0.98 | EGFR (0.44) | EGFRERBB2SLC29A1ADORA3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741372-B2 | Guanylhydrazones useful for treating diseases associated with T cell activation | CYTOKINE PHARMASCIENCES, INC. (US) | 2010-06-22 | — | — | US | claimed |
| US-5565437-A | 2',3'-dideoxy-2'-fluoro-purine nucleosides and methods for using same | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-10-15 | — | — | US | claimed |
| US-5495010-A | Acid stable purine dideoxynucleosides | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-02-27 | — | — | US | claimed |
| EP-0287313-B1 | Acid stable dideoxynucleosides active against the cytopathic effects of human immunodeficiency virus | US COMMERCE (US) | 1995-01-04 | — | — | EP | claimed |
| EP-0464137-A4 | INHIBITION OF HIV USING SYNERGISTIC COMBINATIONS OF NUCLEOSIDE DERIVATIVES | — | 1992-01-15 | — | — | EP | claimed |
| EP-0464137-A1 | INHIBITION OF HIV USING SYNERGISTIC COMBINATIONS OF NUCLEOSIDE DERIVATIVES | ONCOGEN LIMITED PARTNERSHIP (US) | 1992-01-08 | — | — | EP | claimed |
| EP-0428109-A2 | Deoxyfluoronucleoside process | Bristol-Myers Squibb Company (US) | 1991-05-22 | — | — | EP | claimed |
| WO-1990011081-A1 | INHIBITION OF HIV USING SYNERGISTIC COMBINATIONS OF NUCLEOSIDE DERIVATIVES | ONCOGEN LIMITED PARTNERSHIP (US) | 1990-10-04 | — | — | WO | claimed |
| US-20210069259-A1 | COMPOSITIONS AND METHODS FOR TREATING SKIN INFECTIONS AND OTHER DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-03-11 | — | — | US | disclosed |
| EP-2250148-B1 | CRYSTALLINE FORM OF CALCIUM-SALTS OF (3S)-AMINOMETHYL-5-METHYL-HEXANOIC ACIDS AND METHODS OF USE | XENOPORT INC (US) | 2016-08-17 | — | — | EP | disclosed |
| US-8916550-B2 | Compounds for modulating TRPV3 function | HYDRA BIOSCIENCES, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-8603965-B2 | Pharmaceutical composition for the prophylaxis and treatment of HIV infection and its use | FUSOGEN PHARMACEUTICALS, INC. (CN) | 2013-12-10 | — | — | US | disclosed |
| US-8258179-B2 | Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use | XENOPORT, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20110224295-A1 | CRYSTALLINE FORM OF A (3S)-AMINOMETHYL-5-METHYL-HEXANOIC ACID PRODRUG AND METHODS OF USE | XENOPORT, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-5336764-A | 2'-fluorofuranosyl derivatives and novel method of preparing 2'-fluoropyrimidine and 2'-fluoropurine nucleosides | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-08-09 | — | — | US | disclosed |
| WO-1992001700-A1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) | 1992-02-06 | — | — | WO | disclosed |
| EP-0464137-A4 | INHIBITION OF HIV USING SYNERGISTIC COMBINATIONS OF NUCLEOSIDE DERIVATIVES | — | 1992-01-15 | — | — | EP | disclosed |
| EP-0464137-A1 | INHIBITION OF HIV USING SYNERGISTIC COMBINATIONS OF NUCLEOSIDE DERIVATIVES | ONCOGEN LIMITED PARTNERSHIP (US) | 1992-01-08 | — | — | EP | disclosed |
| EP-0428109-A2 | Deoxyfluoronucleoside process | Bristol-Myers Squibb Company (US) | 1991-05-22 | — | — | EP | disclosed |
| WO-1990011081-A1 | INHIBITION OF HIV USING SYNERGISTIC COMBINATIONS OF NUCLEOSIDE DERIVATIVES | ONCOGEN LIMITED PARTNERSHIP (US) | 1990-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224295-A1 | CRYSTALLINE FORM OF A (3S)-AMINOMETHYL-5-METHYL-HEXANOIC ACID PRODRUG AND METHODS OF USE | HEXA, ADSL, CYP2S1 | EGFR 2216/4885ERBB2 4011/4885SLC29A1 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.